Studies have shown that radiopharmaceutical therapy targeting PSMA with β-particle-emitting 177Lu (half-life 6.7 d) is a life-prolonging treatment option for patients with metastatic castration-resistant prostate cancer [6]. Here, FOLH1 is linked to prostate cancer.